Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Total Liabilities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Total Liabilities for 14 consecutive years, with $111.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 8.38% year-over-year to $111.8 million, compared with a TTM value of $111.8 million through Dec 2025, down 8.38%, and an annual FY2025 reading of $111.8 million, down 8.38% over the prior year.
  • Total Liabilities was $111.8 million for Q4 2025 at Fate Therapeutics, up from $109.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $263.6 million in Q2 2021 and bottomed at $109.6 million in Q3 2025.
  • Average Total Liabilities over 5 years is $173.6 million, with a median of $145.4 million recorded in 2023.
  • The sharpest move saw Total Liabilities surged 149.21% in 2021, then tumbled 39.05% in 2023.
  • Year by year, Total Liabilities stood at $242.6 million in 2021, then fell by 8.65% to $221.6 million in 2022, then crashed by 37.82% to $137.8 million in 2023, then dropped by 11.49% to $122.0 million in 2024, then dropped by 8.38% to $111.8 million in 2025.
  • Business Quant data shows Total Liabilities for FATE at $111.8 million in Q4 2025, $109.6 million in Q3 2025, and $110.3 million in Q2 2025.